University of Virginia Health Science Center, Charlottesville, VA 22908, USA.
Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):439-45. doi: 10.1586/egh.11.37.
Dexlansoprazole modified release (MR; Dexilant™), the R-enantiomer of lansoprazole, was approved in the USA in 2009 for the management of erosive esophagitis and nonerosive reflux disease. Dexlansoprazole MR has a unique dual delayed-release delivery system that was designed to address unmet needs that may accompany the use of single-release proton pump inhibitors (PPIs), specifically, their short plasma half-life and requirement for meal-associated dosing. The delivery technology of dexlansoprazole MR is designed to release the drug in two separate pH-dependent phases, the first in the proximal duodenum and the second in the more distal small intestine. This extends plasma concentration and pharmacodynamic effects of dexlansoprazole MR beyond those of single-release PPIs and allows for dosing at any time of the day without regard to meals. This added convenience, along with excellent healing of esophagitis and symptom relief, substantiate its use in patients with gastroesophageal reflux disease requiring PPI treatment.
地塞米松兰索拉唑（MR；Dexilant ™）是兰索拉唑的 R-对映体，于 2009 年在美国获得批准，用于治疗糜烂性食管炎和非糜烂性反流病。地塞米松兰索拉唑 MR 具有独特的双延迟释放传递系统，旨在解决伴随单释放质子泵抑制剂（PPIs）使用而出现的未满足需求，特别是它们的短血浆半衰期和与餐相关的给药需求。地塞米松兰索拉唑 MR 的传递技术旨在以两种独立的 pH 依赖性阶段释放药物，第一阶段在近端十二指肠，第二阶段在更远端的小肠。这延长了地塞米松兰索拉唑 MR 的血浆浓度和药效学效应，超过了单释放 PPI，并允许在一天中的任何时间给药，而无需考虑进餐。这种额外的便利性，加上对食管炎的出色治疗和症状缓解，证实了它在需要 PPI 治疗的胃食管反流病患者中的应用。
